18889881171
Kalkine 0
countryflagUS

AAPL 206.655 1.0044% MSFT 384.86 2.7965% NVDA 106.185 3.3833% GOOGL 158.72 2.1693% GOOG 160.73 1.9084% AMZN 185.5673 2.7504% META 530.91 2.0451% AVGO 187.43 5.9465% BRK-A 795500.0 0.8495% BRK-B 530.135 0.6312% LLY 855.05 3.0901% TSLA 255.535 1.9123% TSM 163.78 3.783% V 336.305 0.5787% JPM 243.935 1.2683% UNH 426.3 -0.3879% NVO 62.61 2.137% WMT 95.78 0.8635% LVMUY 113.69 1.6632% XOM 108.77 1.3039%

Apogee Therapeutics, Inc. Common Stock

Healthcare US APGE

36.45USD
-0.08(0.22%)

Last update at 2025-04-24T16:49:00Z

Day Range

35.8037.08
LowHigh

52 Week Range

20.7872.29
LowHigh

Fundamentals

  • Previous Close 36.53
  • Market Cap2792.23M
  • Volume118213
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.43

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31
Type yearly yearly
Date 2023-12-31 2022-12-31
Income before tax -83.98500M -39.78500M
Minority interest - -
Net income -83.98500M -39.78500M
Selling general administrative 24.58M 2.94M
Selling and marketing expenses - -
Gross profit - -
Reconciled depreciation - -
Ebit -93.09600M -30.76052M
Ebitda -93.00300M -30.72700M
Depreciation and amortization 0.09M 0.03M
Non operating income net other - -
Operating income -93.00300M -30.72700M
Other operating expenses 93.00M 30.73M
Interest expense 0.00000M 9.15M
Tax provision - -
Interest income 9.02M 0.09M
Net interest income 9.02M -9.05800M
Extraordinary items - -
Non recurring - -
Other items - -
Income tax expense -0.09300M -0.03352M
Total revenue 0.00000M 0.00000M
Total operating expenses 93.00M 30.73M
Cost of revenue - -
Total other income expense net 9.02M -9.05800M
Discontinued operations - -
Net income from continuing ops -83.98500M -39.78500M
Net income applicable to common shares - -
Preferred stock and other adjustments - -
Breakdown 2023-12-31 2022-12-31
Type yearly yearly
Date 2023-12-31 2022-12-31
Total assets 401.40M 152.06M
Intangible assets - -
Earning assets - -
Other current assets 2.95M 0.06M
Total liab 21.49M 9.98M
Total stockholder equity 379.91M -39.78500M
Deferred long term liab - -
Other current liab 17.31M 9.56M
Common stock - 4.39M
Capital stock 0.00000M 0.00000M
Retained earnings -123.77000M -39.78500M
Other liab - -
Good will - -
Other assets - -
Cash 118.32M 151.89M
Cash and equivalents - -
Total current liabilities 20.56M 9.98M
Current deferred revenue - -
Net debt -116.28200M -151.89000M
Short term debt 1.10M -
Short long term debt - -
Short long term debt total 2.03M -
Other stockholder equity 503.35M 39.78M
Property plant equipment - -
Total current assets 398.41M 152.06M
Long term investments - -
Net tangible assets - -
Short term investments 277.14M 0.00000M
Net receivables - -
Long term debt - -
Inventory - -
Accounts payable 2.14M 0.42M
Total permanent equity - -
Noncontrolling interest in consolidated entity - -
Temporary equity redeemable noncontrolling interests - -
Accumulated other comprehensive income 0.33M -221.64500M
Additional paid in capital - -
Common stock total equity - -
Preferred stock total equity - -
Retained earnings total equity - -
Treasury stock - -
Accumulated amortization - -
Non currrent assets other 0.10M -
Deferred long term asset charges - -
Non current assets total 3.00M 0.00000M
Capital lease obligations 2.03M 0.00000M
Long term debt total - -
Breakdown 2023-12-31 2022-12-31
Type yearly yearly
Date 2023-12-31 2022-12-31
Investments -273.91000M 0.00000M
Change to liabilities - -
Total cashflows from investing activities - -
Net borrowings - -
Total cash from financing activities 315.39M 0.18M
Change to operating activities - -
Net income -83.98500M -39.78500M
Change in cash -33.57400M -16.24338M
Begin period cash flow 151.89M 168.13M
End period cash flow 118.32M 151.89M
Total cash from operating activities -74.76100M -16.42700M
Issuance of capital stock 315.39M 168.32M
Depreciation - -
Other cashflows from investing activities - -
Dividends paid - -
Change to inventory - -
Change to account receivables - -
Sale purchase of stock - -
Other cashflows from financing activities 0.32M 0.18M
Change to netincome - -
Capital expenditures 0.17M 0.00000M
Change receivables - -
Cash flows other operating - -
Exchange rate changes - -
Cash and cash equivalents changes - -
Change in working capital 6.11M 9.81M
Stock based compensation 6.10M 2.14M
Other non cash items -2.98400M 11.40M
Free cash flow -74.92800M -16.42700M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x)
APGE
Apogee Therapeutics, Inc. Common Stock		 -0.08 0.22% 36.45 - - - 3.87
NVO
Novo Nordisk A/S		 1.31 2.14% 62.61 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.30 2.09% 63.55 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.42 0.29% 491.00 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.92 0.50% 590.76 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Apogee Therapeutics, Inc. Common Stock

221 Crescent Street, Waltham, MA, United States, 02453

Key Executives

Name Title Year Born
Dr. Michael Thomas Henderson M.D. CEO & Director 1990
Ms. Jane Pritchett V. Henderson Chief Financial Officer 1966
Dr. Carl Linden Dambkowski M.D. Chief Medical Officer 1986
Dr. Rebecca Dabora Ph.D. Chief Technical Officer 1959
Ms. Noel Kurdi Vice President of Investor Relations NA
Mr. Matthew Batters J.D. General Counsel 1976
Ms. Emily Cox VP & Head of People NA
Ms. Wendy Aspden-Curran Senior Vice President of Clinical Operations NA
Dr. Drew Badger Ph.D. Senior VP and Head of Regulatory Affairs & Toxicology NA
Ms. Monica Forbes Senior Vice President of Finance 1976

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.